Alternatives to CellCentric

A global oncology company developing and commercializing innovative cancer treatments.

Global biopharmaceutical company focused on oncology and neuroscience treatments.

Biotechnology company developing cell and gene therapies for serious diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

A global leader in clinical pharmacology and bioanalytical sciences.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Developing oral small molecule medicines for immunological and chronic diseases.

Pioneering vision restoration therapies for severe retinal degenerations.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

A biotechnology company focused on oncology drug discovery.

Developing first-in-class oral therapy for BK polyomavirus infections.

Immunotherapy company targeting oncology and autoimmune diseases.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Developing novel male contraceptives.

Scalable, one-time curative in-vivo gene editing therapies.

Clinical-stage immunotherapy company developing novel treatments for cancer.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

A biopharmaceutical company focused on drug discovery and development.

Advancing targeted alpha therapies.

Developing a new histotripsy therapeutic platform for cancer treatment.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Biopharmaceutical company developing T-cell therapies for solid tumor cancers.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

Accelerating medicine for the people who need it, prescribe it, and create it.

Developing novel therapeutics for inflammatory and hypoxic diseases.

Discovering and developing first-in-class antibody therapeutics by identifying protective antibodies from disease-resilient individuals.

Clinical-stage biotech company developing transformative cytokine therapies.

Pioneering next-generation bispecific ADCs for cancer treatment.

Venture philanthropy organization accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD).

Biotechnology company defining membrane protein spatial relationships to create novel therapeutics for cancer and autoimmune diseases.